Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 168

1.

Pharmacoeconomics of angiotensin II antagonists in type 2 diabetic patients with nephropathy: implications for decision making.

Boersma C, Atthobari J, Gansevoort RT, de Jong-Van den Berg LT, de Jong PE, de Zeeuw D, Annemans LJ, Postma MJ.

Pharmacoeconomics. 2006;24(6):523-35. Review.

PMID:
16761901
2.

Type 2 diabetes: RENAAL and IDNT--the emergence of new treatment options.

Sica DA, Bakris GL.

J Clin Hypertens (Greenwich). 2002 Jan-Feb;4(1):52-7.

3.

What have we learned from the current trials?

Abbott KC, Bakris GL.

Med Clin North Am. 2004 Jan;88(1):189-207. Review.

PMID:
14871059
4.

Renal and cardiovascular protection in type 2 diabetes mellitus: angiotensin II receptor blockers.

Deferrari G, Ravera M, Deferrari L, Vettoretti S, Ratto E, Parodi D.

J Am Soc Nephrol. 2002 Nov;13 Suppl 3:S224-9. Review.

5.

[The role of angiotensin II AT1-receptor antagonists in renal and cardiac protection in type-2 diabetes mellitus].

Ravera M, Deferrari L, Ratto E, Vettoretti S, Parodi D, Deferrari G.

Ital Heart J Suppl. 2003 Mar;4(3):210-6. Review. Italian.

PMID:
12784755
6.

Losartan in diabetic nephropathy.

Perico N, Ruggenenti P, Remuzzi G.

Expert Rev Cardiovasc Ther. 2004 Jul;2(4):473-83. Review.

PMID:
15225108
7.

Pharmacologic management of diabetic nephropathy.

Vivian EM, Rubinstein GB.

Clin Ther. 2002 Nov;24(11):1741-56; discussion 1719. Review.

PMID:
12501871
8.
10.

Economic evaluation of angiotensin receptor blockers in type 2 diabetes, hypertension, and nephropathy.

Ravera M, Re M, Vettoretti S.

J Am Soc Nephrol. 2006 Apr;17(4 Suppl 2):S44-8. Review.

11.
12.

Angiotensin II receptor blockers for the treatment of hypertension.

See S.

Expert Opin Pharmacother. 2001 Nov;2(11):1795-804. Review.

PMID:
11825317
13.

Current recommendations for the treatment of hypertension: are they still valid?

Moser M.

J Hypertens Suppl. 2002 Feb;20(1):S3-10.

PMID:
11996197
14.

The impact of losartan on the lifetime incidence of end-stage renal disease and costs in patients with type 2 diabetes and nephropathy.

Carides GW, Shahinfar S, Dasbach EJ, Keane WF, Gerth WC, Alexander CM, Herman WH, Brenner BM; RENAAL Investigators..

Pharmacoeconomics. 2006;24(6):549-58.

PMID:
16761903
15.

Cost-effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in newly diagnosed type 2 diabetes in Germany.

Adarkwah CC, Gandjour A.

Int J Technol Assess Health Care. 2010 Jan;26(1):62-70. doi: 10.1017/S0266462309990584.

PMID:
20059782
16.

[Cost-effectiveness of angiotensin receptor blockers in patients with type 2 diabetes mellitus and nephropathy in Israel].

Berar-Yanay N, Leshno M, Hertzeanu L, Weintrob N.

Harefuah. 2008 Mar;147(3):211-5, 278. Hebrew.

PMID:
18488861
17.
18.

Angiotensin II-receptor blockers: clinical relevance and therapeutic role.

Rodgers JE, Patterson JH.

Am J Health Syst Pharm. 2001 Apr 15;58(8):671-83. Review. Erratum in: Am J Health Syst Pharm 2001 Sep 1;58(17):1658.

PMID:
11329759
19.

Losartan reduces the costs of diabetic end-stage renal disease: an Asian perspective.

Seng WK, Hwang SJ, Han DC, Teong CC, Chan J, Burke TA, Carides GW, Choi YJ.

Nephrology (Carlton). 2005 Oct;10(5):520-4.

PMID:
16221106
20.

Role of angiotensin receptor blockers in diabetes: implications of recent clinical trials.

McFarlane SI.

Expert Rev Cardiovasc Ther. 2009 Nov;7(11):1363-71. doi: 10.1586/erc.09.115. Review.

PMID:
19900019

Supplemental Content

Support Center